Purpose Integrin subunit beta 4 (beta 4) has been proposed to play an important role in colon cancer progression through its involvement in hemidesmosome disassembly processes and tumor cell... Show morePurpose Integrin subunit beta 4 (beta 4) has been proposed to play an important role in colon cancer progression through its involvement in hemidesmosome disassembly processes and tumor cell migration. However, the association between beta 4 expression and clinicopathological outcomes in colon cancer remains unclear.Methods Expression of beta 4 was assessed by immunohistochemistry in a large cohort of 651 colon cancer patients, the largest colon cancer cohort so far. Chi-squared tests were used to study the association between beta 4 expression and clinicopathological features. Overall and disease-free survival were assessed by Cox proportional hazard models.Results Loss of beta 4 expression was associated with local tumor invasion. Only 17.9% of the pT1 tumors displayed weak beta 4 expression level versus 28.1% of pT4 tumors, and 25.0% of the pT1 tumors had a high expression level versus 8.6% of the pT4 tumors (p = 0.012). No association between beta 4 expression and overall (p = 0.845) or disease-free survival (p = 0.767) was encountered, which disputes the role of beta 4 as a biomarker of malignant behavior in colon cancer.Conclusion Contradictory reports have suggested opposite roles for beta 4 expression in (colon) cancer progression. In the present large cohort of colon cancer patients, we found that beta 4 expression was not associated with worse clinical prognosis, but decreased with advanced pathological tumor stage. Future studies should establish whether loss of beta 4 expression promotes invasive characteristics of colon cancer cells. Show less
Purpose Integrin subunit beta 4 (beta 4) has been proposed to play an important role in colon cancer progression through its involvement in hemidesmosome disassembly processes and tumor cell... Show morePurpose Integrin subunit beta 4 (beta 4) has been proposed to play an important role in colon cancer progression through its involvement in hemidesmosome disassembly processes and tumor cell migration. However, the association between beta 4 expression and clinicopathological outcomes in colon cancer remains unclear.Methods Expression of beta 4 was assessed by immunohistochemistry in a large cohort of 651 colon cancer patients, the largest colon cancer cohort so far. Chi-squared tests were used to study the association between beta 4 expression and clinicopathological features. Overall and disease-free survival were assessed by Cox proportional hazard models.Results Loss of beta 4 expression was associated with local tumor invasion. Only 17.9% of the pT1 tumors displayed weak beta 4 expression level versus 28.1% of pT4 tumors, and 25.0% of the pT1 tumors had a high expression level versus 8.6% of the pT4 tumors (p = 0.012). No association between beta 4 expression and overall (p = 0.845) or disease-free survival (p = 0.767) was encountered, which disputes the role of beta 4 as a biomarker of malignant behavior in colon cancer.Conclusion Contradictory reports have suggested opposite roles for beta 4 expression in (colon) cancer progression. In the present large cohort of colon cancer patients, we found that beta 4 expression was not associated with worse clinical prognosis, but decreased with advanced pathological tumor stage. Future studies should establish whether loss of beta 4 expression promotes invasive characteristics of colon cancer cells. Show less